Replies to post #444 on Fate Therapeutics Inc (FATE)

[jondoeuk]

I think that is likely.

On the topic of NKG2DLs, one group engineered an NKG2D CAR-NK cell product (which would target ULBP1-6 as well) that is unaffected by TGFB or soluble NKG2DLs, is able to kill MDSCs and rescue impaired CAR-Ts https://aacrjournals.org/cancerimmunolres/article/7/3/363/469550/NK-Cells-Expressing-a-Chimeric-Activating-Receptor